Bamlanivimab plus etesevimab for the treatment of COVID-19 in high-risk ambulatory patients including those with diabetes

Tahbaz, A.; Dougan, M.; Nirula, A.; Gottlieb, R.; Azizad, M.; Mocherla, B.; Chen, P.; Huhn, G.; Adams, A.; Schade, A.; Sabo, J.; Patel, D.; Klekotka, P.; Shen, L.; Skovronsky, D.

Main content 1 Search 2 Footer 3

+A A -A High contrast

WHO COVID-19 Research Database

News/Update/Help

Advanced Search

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

Bamlanivimab plus etesevimab for the treatment of COVID-19 in high-risk ambulatory patients including those with diabetes

Tahbaz, A.; Dougan, M.; Nirula, A.; Gottlieb, R.; Azizad, M.; Mocherla, B.; Chen, P.; Huhn, G.; Adams, A.; Schade, A.; Sabo, J.; Patel, D.; Klekotka, P.; Shen, L.; Skovronsky, D..

Diabetologia ; 64(SUPPL 1):361-361, 2021.

Article in English | Web of Science | ID: covidwho-1431634

Search on Google

Print

XML

Collection: Databases of international organizations Database: Web of Science Type of study: Prognostic study Language: English Journal: Diabetologia Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Search on Google

Print

XML

Collection: Databases of international organizations Database: Web of Science Type of study: Prognostic study Language: English Journal: Diabetologia Year: 2021 Document Type: Article